FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164886552> ?p ?o ?g. }

• W2164886552 endingPage "993" @default.
• W2164886552 startingPage "986" @default.
• W2164886552 abstract "Abstract Fifteen patients with refractory AML were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine kinase 3 (Flt3), Kit, vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) receptors. Separate cohorts of patients received SU11248 for 4-week cycles followed by either a 2- or a 1-week rest period. At the starting dose level of 50 mg (n = 13), no dose-limiting toxicities were observed. The most frequent grade 2 toxicities were edema, fatigue, and oral ulcerations. Two fatal bleedings possibly related to the disease, one from a concomitant lung cancer and one cerebral bleeding, were observed. At the 75 mg dose level (n = 2), one case each of grade 4 fatigue, hypertension, and cardiac failure was observed, and this dose level was abandoned. All patients with FLT3 mutations (n = 4) had morphologic or partial responses compared with 2 of 10 evaluable patients with wild-type FLT3. Responses, although longer in patients with mutated FLT3, were of short duration. Reductions of cellularity and numbers of Ki-67+, phospho-Kit+, phospho–kinase domain–containing receptor–positive (phospho-KDR+), phospho–signal transducer and activator of transcription 5–positive (phospho-STAT5+), and phospho-Akt+ cells were detected in bone marrow histology analysis. In summary, monotherapy with SU11248 induced partial remissions of short duration in acute myeloid leukemia (AML) patients. Further evaluation of this compound, for example in combination with chemotherapy, is warranted." @default.
• W2164886552 created "2016-06-24" @default.
• W2164886552 creator A5008186001 @default.
• W2164886552 creator A5009768388 @default.
• W2164886552 creator A5014161698 @default.
• W2164886552 creator A5014718652 @default.
• W2164886552 creator A5025105470 @default.
• W2164886552 creator A5029052230 @default.
• W2164886552 creator A5049514341 @default.
• W2164886552 creator A5051371787 @default.
• W2164886552 creator A5052479430 @default.
• W2164886552 creator A5054751099 @default.
• W2164886552 creator A5068067507 @default.
• W2164886552 creator A5075821880 @default.
• W2164886552 creator A5078774955 @default.
• W2164886552 creator A5080534634 @default.
• W2164886552 creator A5084039929 @default.
• W2164886552 creator A5086016311 @default.
• W2164886552 creator A5089395073 @default.
• W2164886552 date "2005-02-01" @default.
• W2164886552 modified "2023-10-18" @default.
• W2164886552 title "A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease" @default.
• W2164886552 cites W135651168 @default.
• W2164886552 cites W1542395305 @default.
• W2164886552 cites W1567732942 @default.
• W2164886552 cites W182858095 @default.
• W2164886552 cites W1919339218 @default.
• W2164886552 cites W1963846089 @default.
• W2164886552 cites W1966376566 @default.
• W2164886552 cites W1978469902 @default.
• W2164886552 cites W1978544029 @default.
• W2164886552 cites W2009069027 @default.
• W2164886552 cites W2012852444 @default.
• W2164886552 cites W2031008930 @default.
• W2164886552 cites W2041027929 @default.
• W2164886552 cites W2046507292 @default.
• W2164886552 cites W2083030882 @default.
• W2164886552 cites W2086626683 @default.
• W2164886552 cites W2101886636 @default.
• W2164886552 cites W2105434446 @default.
• W2164886552 cites W2118781121 @default.
• W2164886552 cites W2125877707 @default.
• W2164886552 cites W2130864403 @default.
• W2164886552 cites W2132912591 @default.
• W2164886552 cites W2149032069 @default.
• W2164886552 cites W2150470057 @default.
• W2164886552 cites W2155591820 @default.
• W2164886552 cites W2329648702 @default.
• W2164886552 cites W69990049 @default.
• W2164886552 doi "https://doi.org/10.1182/blood-2004-05-1846" @default.
• W2164886552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15459012" @default.
• W2164886552 hasPublicationYear "2005" @default.
• W2164886552 type Work @default.
• W2164886552 sameAs 2164886552 @default.
• W2164886552 citedByCount "466" @default.
• W2164886552 countsByYear W21648865522012 @default.
• W2164886552 countsByYear W21648865522013 @default.
• W2164886552 countsByYear W21648865522014 @default.
• W2164886552 countsByYear W21648865522015 @default.
• W2164886552 countsByYear W21648865522016 @default.
• W2164886552 countsByYear W21648865522017 @default.
• W2164886552 countsByYear W21648865522018 @default.
• W2164886552 countsByYear W21648865522019 @default.
• W2164886552 countsByYear W21648865522020 @default.
• W2164886552 countsByYear W21648865522021 @default.
• W2164886552 countsByYear W21648865522022 @default.
• W2164886552 countsByYear W21648865522023 @default.
• W2164886552 crossrefType "journal-article" @default.
• W2164886552 hasAuthorship W2164886552A5008186001 @default.
• W2164886552 hasAuthorship W2164886552A5009768388 @default.
• W2164886552 hasAuthorship W2164886552A5014161698 @default.
• W2164886552 hasAuthorship W2164886552A5014718652 @default.
• W2164886552 hasAuthorship W2164886552A5025105470 @default.
• W2164886552 hasAuthorship W2164886552A5029052230 @default.
• W2164886552 hasAuthorship W2164886552A5049514341 @default.
• W2164886552 hasAuthorship W2164886552A5051371787 @default.
• W2164886552 hasAuthorship W2164886552A5052479430 @default.
• W2164886552 hasAuthorship W2164886552A5054751099 @default.
• W2164886552 hasAuthorship W2164886552A5068067507 @default.
• W2164886552 hasAuthorship W2164886552A5075821880 @default.
• W2164886552 hasAuthorship W2164886552A5078774955 @default.
• W2164886552 hasAuthorship W2164886552A5080534634 @default.
• W2164886552 hasAuthorship W2164886552A5084039929 @default.
• W2164886552 hasAuthorship W2164886552A5086016311 @default.
• W2164886552 hasAuthorship W2164886552A5089395073 @default.
• W2164886552 hasConcept C121608353 @default.
• W2164886552 hasConcept C126322002 @default.
• W2164886552 hasConcept C2776694085 @default.
• W2164886552 hasConcept C2778729363 @default.
• W2164886552 hasConcept C2778820342 @default.
• W2164886552 hasConcept C2778822529 @default.
• W2164886552 hasConcept C2779490328 @default.
• W2164886552 hasConcept C71924100 @default.
• W2164886552 hasConcept C90924648 @default.
• W2164886552 hasConceptScore W2164886552C121608353 @default.
• W2164886552 hasConceptScore W2164886552C126322002 @default.
• W2164886552 hasConceptScore W2164886552C2776694085 @default.
• W2164886552 hasConceptScore W2164886552C2778729363 @default.

• next